UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
—————————
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
—————————
For the month of September 2006
Commission File Number: 001-31368
SANOFI-AVENTIS
(Translation of registrant’s name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. |
| Form 20-F x | Form 40-F o |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____ |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____ |
| Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. |
| Yes o | No x |
| If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________ |
In September 2006, sanofi-aventis issued the press releases attached hereto as Exhibit 99.1, 99.2, 99.3 which are incorporated herein by reference.
Exhibit List
|
Exhibit No. |
Description |
|
Exhibit 99.1 |
Press Release dated September 19, 2006: “sanofi pasteur broadens pandemic preparedness with first clinical trial of novel cell based h7n1 vaccine” |
|
Exhibit 99.2 |
Press Release dated September 21, 2006: “Plavix® Preliminary Injunction Appeal - Apotex’s Motion to Stay Rejected - Court sets Calendar for Appeal” |
|
Exhibit 99.3 |
Press Release dated September 22, 2006: “taxotere®receives positive opinion from the committee for medicinal products for human use (chmp) recommending approval in the european union for head and neck cancer” |
|
|
2 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Dated: September 22, 2006 |
SANOFI-AVENTIS | |
| By: | /s/ Patricia Kodyra | |
| Name: Patricia Kodyra Title: Associate Vice President Financial and Securities Law |
||
|
|
3 |
|
Exhibit Index
|
Exhibit No. |
Description |
|
Exhibit 99.1 |
Press Release dated September 19, 2006: “sanofi pasteur broadens pandemic preparedness with first clinical trial of novel cell based h7n1 vaccine” |
|
Exhibit 99.2 |
Press Release dated September 21, 2006: “Plavix® Preliminary Injunction Appeal - Apotex’s Motion to Stay Rejected - Court sets Calendar for Appeal” |
|
Exhibit 99.3 |
Press Release dated September 22, 2006: “taxotere®receives positive opinion from the committee for medicinal products for human use (chmp) recommending approval in the european union for head and neck cancer” |
|
|
4 |
|